Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy (FIREFISH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02913482
Recruitment Status : Active, not recruiting
First Posted : September 23, 2016
Results First Posted : January 8, 2021
Last Update Posted : September 13, 2021
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Tracking Information
First Submitted Date  ICMJE September 21, 2016
First Posted Date  ICMJE September 23, 2016
Results First Submitted Date  ICMJE November 10, 2020
Results First Posted Date  ICMJE January 8, 2021
Last Update Posted Date September 13, 2021
Actual Study Start Date  ICMJE December 24, 2016
Actual Primary Completion Date November 14, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 14, 2020)
  • Part 1: Selected Part 2 Dose of Risdiplam [ Time Frame: Minimum of 2 weeks at steady state exposure ]
    All safety, tolerability, PK and PD data available up to the clinical cut-off date of 5 January 2018, plus data that became available prior to the database snapshot on 6 February 2018 were included in the Internal Monitoring Committee (IMC) review. The IMC was responsible for selecting the dose for Part 2 of the study (pivotal dose). An external Independent Data Monitoring Committee (iDMC) reviewed data from Part 1 and confirmed the dose-selection decision of the IMC. The dose for Part 2 selected by the IMC was a dose that: 1.Was judged to be safe and well-tolerated, based on all available safety data from Part 1 and as confirmed by the iDMC; 2. Resulted in an exposure at steady-state below the exposure cap (mean value) of AUC0-24h,ss 2000 ng*h/mL (adjusted for free-fraction, if required); 3. Resulted in an SMN protein increase that was expected to be clinically relevant.
  • Part 2: Percentage of Infants Who Are Sitting Without Support for at Least 5 Seconds as Assessed by Item 22 of the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III) at Month 12 [ Time Frame: At Month 12 (Up to the Clinical Cut-off Date (CCOD) of 14 November 2019) ]
    The BSID-III is a standardized assessment commonly used to evaluate development across five domains in infants and young children aged between 1 and 42 months. The gross motor subscale of the BSID-III is evaluated based on the linear and hierarchical obtainment of motor skills, as seen in typically developing children. The gross motor scale consists of 72 items scored at 0 (unable to perform the activity) or 1 (criteria for item achieved). Item 22 is not considered achieved if the infant sits alone for less than 5 seconds before losing balance and falling over, or if the infant uses his or her arms to prop him- or herself up. The assessment was video recorded at study sites and reviewed/scored by two independent raters. 90% CI for one sample binomial was computed using Clopper-Pearson (exact) method.
Original Primary Outcome Measures  ICMJE
 (submitted: September 22, 2016)
  • Recommended Part 2 Dose of RO7034067 [ Time Frame: 2 weeks ]
  • Part 2: Percentage of Infants who are Sitting Without Support at 12-months of Treatment Assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler development Third Edition (BSID-III) [ Time Frame: Month 12 ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 14, 2020)
  • Part 2: Percentage of Infants Who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12 [ Time Frame: At Month 12 (Up to the Clinical Cut-off Date (CCOD) of 14 November 2019) ]
    The CHOP-INTEND instrument was developed to evaluate motor function in infants with SMA from the ages of 1.4 to 37.9 months. It consists of 16 items, where each item assesses a specific motor task graded on a scale of 0 to 4, where zero is no response and 4 is a complete response. The total score ranges from 0 to 64, with higher scores consistent with better motor function. 90% CI for one sample binomial was computed using Clopper-Pearson (exact) method.
  • Part 2: Percentage of Infants Achieving an Increase of >/= 4 Points in Their CHOP-INTEND Score From Baseline at Month 8 and 12 [ Time Frame: At Month 8 and Month 12 (Up to the CCOD of 14 November 2019) ]
    The CHOP-INTEND instrument was developed to evaluate motor function in infants with SMA from the ages of 1.4 to 37.9 months. It consists of 16 items, where each item assesses a specific motor task graded on a scale of 0 to 4, where zero is no response and 4 is a complete response. The total score ranges from 0 to 64, with higher scores consistent with better motor function. 90% CI for one sample binomial was computed using Clopper-Pearson (exact) method.
  • Part 2: Percentage of Infants Achieving Head Control (Defined as a Score of >/= 3 for CHOP-INTEND Item 12) at Month 8 and 12 [ Time Frame: At Month 8 and Month 12 (Up to the CCOD of 14 November 2019) ]
    The CHOP-INTEND instrument was developed to evaluate motor function in infants with SMA from the ages of 1.4 to 37.9 months. It consists of 16 items, where each item assesses a specific motor task graded on a scale of 0 to 4, where zero is no response and 4 is a complete response. The total score ranges from 0 to 64, with higher scores consistent with better motor function. 90% CI for one sample binomial was computed using Clopper-Pearson (exact) method.
  • Part 2: Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    The BSID-III is a standardized assessment commonly used to evaluate development across five domains in infants and young children aged between 1 and 42 months. The gross motor subscale of the BSID-III is evaluated based on the linear and hierarchical obtainment of motor skills, as seen in typically developing children. The gross motor scale consists of 72 items scored at 0 (unable to perform the activity) or 1 (criteria for item achieved). In this study the gross motor scale was assessed in a modified way compared with the standard administration. A total raw score was calculated by summing the item scores to give a maximum possible score of 72.
  • Part 2: Percentage of Infants Who Achieve the Attainment Levels of a Subset of Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 8 [ Time Frame: At Month 8 (Up to the CCOD of 14 November 2019) ]
    The HINE was designed to evaluate infants between 2 months and 24 months of age. It is a simple and standardized instrument that includes 26 items assessing different aspects of neurological examinations, such as cranial nerves, posture, movements, tone, and reflexes. In this study, Module 2 of the HINE (HINE-2) was assessed. The HINE-2 evaluates 8 developmental milestones (head control, sitting, voluntary grasp, ability to kick, rolling, crawling, standing, and walking) scored on a 3, 4, or 5-point scale, with 0 indicating inability to perform a task and a score of 2, 3, or 4 (depending on the task) indicating full milestone development. The total score is calculated by summing the item scores to give a maximum possible score of 26. This measure represents subset numbers at Month 8 for head control, ability to kick and rolling milestones only.
  • Part 2: Percentage of Infants Who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    The HINE was designed to evaluate infants between 2 months and 24 months of age. It is a simple and standardized instrument that includes 26 items assessing different aspects of neurological examinations, such as cranial nerves, posture, movements, tone, and reflexes. In this study, Module 2 of the HINE (HINE-2) was assessed. The HINE-2 evaluates 8 developmental milestones (head control, sitting, voluntary grasp, ability to kick, rolling, crawling, standing, and walking) scored on a 3, 4, or 5-point scale, with 0 indicating inability to perform a task and a score of 2, 3, or 4 (depending on the task) indicating full milestone development. The total score is calculated by summing the item scores to give a maximum possible score of 26.
  • Part 2: Percentage of Motor Milestone Responders as Assessed by HINE-2 at Month 12 [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    The HINE-2 evaluates 8 developmental milestones scored on a 3, 4, or 5-point scale, with 0 indicating inability to perform a task and a score of 2, 3, or 4 (depending on the task) indicating full milestone development. The total score is calculated by summing the item scores to give a maximum possible score of 26. For the motor milestone responder definition, an improvement in a motor milestone is defined as at least a 2-point increase in ability to kick (or maximal score) or a 1-point increase in head control, rolling, sitting, crawling, standing, or walking. Worsening is similarly defined as a 2-point decrease in ability to kick (or lowest score) or a 1-point decrease in head control, rolling, sitting, crawling, standing, or walking. Voluntary grasp is excluded from the definition. An infant is classified as a responder if more motor milestones show improvement than show worsening. 90% CI for one sample binomial was computed using Clopper-Pearson (exact) method.
  • Part 2: Highest Motor Milestone Achieved by Month 12 as Assessed in the BSID-III Gross Motor Scale [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    The BSID-III is a standardized assessment commonly used to evaluate development across five domains in infants and young children aged between 1 and 42 months. The gross motor subscale of the BSID-III is evaluated based on the linear and hierarchical obtainment of motor skills, as seen in typically developing children. The gross motor scale consists of 72 items scored at 0 (unable to perform the activity) or 1 (criteria for item achieved). This measure included 6 milestones: Item 9 'Controls head while upright for 15 seconds', Item 14 'Rolls from side to back', Item 22 'Sits without support for 5 seconds', Item 30 'Crawls on stomach', Item 40 'Stands alone' and Item 42 'Walks alone'.
  • Part 2: Percentage of Infants Who Are Sitting Without Support for at Least 5 Seconds as Assessed by Item 22 of the BSID-III Gross Motor Scale at Month 24 [ Time Frame: Month 24 ]
  • Part 2: Percentage of Infants Who Are Sitting Without Support for at Least 30 Seconds as Assessed by Item 26 of the BSID-III Gross Motor Scale at Month 24 [ Time Frame: Month 24 ]
  • Part 2: Percentage of Infants Who Are Standing Alone as Assessed by Item 40 of the BSID-III Gross Motor Scale at Month 24 [ Time Frame: Month 24 ]
  • Part 2: Percentage of Infants Who Are Walking Alone as Assessed by Item 42 of the BSID-III Gross Motor Scale at Month 24 [ Time Frame: Month 24 ]
  • Part 2: Time to Death [ Time Frame: Baseline up to 12 Months (Up to the CCOD of 14 November 2019) ]
    The median time to event was estimated using Kaplan-Meier methodology. 90% CI was estimated using the method of Brookmeyer and Crowley.
  • Part 2: Time to Death or Permanent Ventilation [ Time Frame: Baseline up to 12 Months (Up to the CCOD of 14 November 2019) ]
    Permanent ventilation is defined as >/=16 hours of non-invasive ventilation per day or intubation for >21 consecutive days in the absence of, or following the resolution of, an acute reversible event; or tracheostomy. Permanent ventilation events were reviewed and confirmed by an independent adjudication committee. The median time to event was estimated using Kaplan-Meier methodology. 90% CI was estimated using the method of Brookmeyer and Crowley.
  • Part 2: Time to Permanent Ventilation [ Time Frame: Baseline up to 12 Months (Up to the CCOD of 14 November 2019) ]
    Permanent ventilation is defined as >/=16 hours of non-invasive ventilation per day or intubation for >21 consecutive days in the absence of, or following the resolution of, an acute reversible event; or tracheostomy. Permanent ventilation events were reviewed and confirmed by an independent adjudication committee. The median time to event was estimated using Kaplan-Meier methodology. 90% CI was estimated using the method of Brookmeyer and Crowley.
  • Part 2: Percentage of Infants Who Are Alive Without Permanent Ventilation at Month 12 [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    Permanent ventilation is defined as >/=16 hours of non-invasive ventilation per day or intubation for >21 consecutive days in the absence of, or following the resolution of, an acute reversible event; or tracheostomy. Permanent ventilation events were reviewed and confirmed by an independent adjudication committee. Kaplan-Meier methodology was used to estimate the percentages. 90% CI was computed using the complementary log-log transformation.
  • Part 2: Percentage of Infants Who Are Alive at Month 12 [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    Kaplan-Meier methodology was used to estimate the percentages. 90% CI was computed using the complementary log-log transformation.
  • Part 2: Percentage of Infants Who Are Without Permanent Ventilation at Month 12 [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    Permanent ventilation is defined as >/=16 hours of non-invasive ventilation per day or intubation for >21 consecutive days in the absence of, or following the resolution of, an acute reversible event; or tracheostomy. Permanent ventilation events were reviewed and confirmed by an independent adjudication committee. Kaplan-Meier methodology was used to estimate the percentages. 90% CI was computed using the complementary log-log transformation.
  • Part 2: Percentage of Infants Who Achieve a Reduction of At Least 30 Degrees in Phase Angle From Baseline, as Measured by Respiratory Plethysmography (RP) at Month 12 [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    RP measures the degree of synchrony between abdominal and thoracic cage-driven breathing. The weakness of intercostal muscles leads to asynchrony of the thorax with the diaphragm, resulting in inefficient and paradoxical breathing patterns. The degree of synchrony between the movement of the chest wall and abdomen during the respiratory cycle can be expressed as the phase angle between the two compartments and measured by placing two RP bands around the thorax and abdomen. In paradoxical breathing, the phase angle is reversed compared with the normal ventilation cycle. A phase angle of 0° indicates perfect in-phase movement, while a value of 180° indicates completely out-of-phase movement between the two compartments. In this measure, 8 or more valid breaths were used to determine the phase angle at each visit; the calculation was not performed if fewer than 8 valid breaths had been measured. 90% CI for one sample binomial was computed using Clopper-Pearson (exact) method.
  • Part 2: Percentage of Infants Not Requiring Respiratory Support (Invasive or Non-Invasive) at Month 12 [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    90% CI for one sample binomial was computed using Clopper-Pearson (exact) method.
  • Part 2: Percentage of Infants Able to Feed Orally at Month 12 [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    Able to feed orally includes participants fed orally and participants fed via a combination of oral and tube feeding. 90% CI for one sample binomial was computed using Clopper-Pearson (exact) method.
  • Part 1: Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs) [ Time Frame: From first dose of risdiplam up to a minimum of 12 months (Up to CCOD 27 February 2019) ]
    An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
  • Part 2: Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs) [ Time Frame: From first dose of risdiplam up to a minimum of 12 months (Up to the CCOD of 14 November 2019) ]
    An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
  • Part 2: Percentage of Participants With AEs and SAEs Leading to Treatment Discontinuation [ Time Frame: From first dose of risdiplam up to a minimum of 12 months (Up to the CCOD of 14 November 2019) ]
    An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
  • Part 2: Percentage of Participants With AEs and SAEs Leading to Treatment Modification/Interruption [ Time Frame: From first dose of risdiplam up to a minimum of 12 months (Up to the CCOD of 14 November 2019) ]
    An adverse event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
  • Part 2: Anthropometric Examination of Weight Measured in Kilograms [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    Anthropometric examination included weight, height, head circumference and chest circumference.
  • Part 2: Anthropometric Examination of Height, Head Circumference and Chest Circumference Measured in Centimeter [ Time Frame: At Month 12 (Up to the CCOD of 14 November 2019) ]
    Anthropometric examination included weight, height, head circumference and chest circumference.
  • Part 2: Maximum Plasma Concentration (Cmax) of Risdiplam [ Time Frame: 2, 4, 6, hours PoD on Day 1; PrD (Hour 0) on Days 2, 14, 119, 245, 364, 427, 490, 609, 728; PrD and 2, 4, 6 hours PoD on Days 28, 56, 182, 301, 546, 672 ]
  • Part 2: Area Under the Curve (AUC) of Risdiplam [ Time Frame: 2, 4, 6, hours PoD on Day 1; PrD (Hour 0) on Days 2, 14, 119, 245, 364, 427, 490, 609, 728; PrD and 2, 4, 6 hours PoD on Days 28, 56, 182, 301, 546, 672 ]
  • Part 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam [ Time Frame: PrD (Hour 0) on Days 2, 14, 28, 56, 119, 182, 301, 546, 672 ]
  • Survival of Motor Neuron (SMN) Protein Levels in Blood [ Time Frame: Days 1, 14 (Part 1 only), 28, 119, 245, 364, 609, 728 ]
  • Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood [ Time Frame: Days 1, 14 (Part 1 only), 28, 245, 364, 609, 728 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: September 22, 2016)
  • Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to 25 months ]
  • Part 1: Maximum plasma concentration (Cmax) of RO7034067 [ Time Frame: Pre-dose (PrD) (Hour 0) and 2, 4, 6, hour post-dose (PoD) on Days 1, 28, 84, 364, 546, 728; PrD on Day 2; PrD and 4 hours PoD on Days 7, 14, 56, 119, 182, 245, 301, 427, 490, 609, 672 ]
  • Part 2: Maximum plasma concentration (Cmax) of RO7034067 [ Time Frame: 2, 4, 6, hours PoD on Day 1; PrD (Hour 0) on Days 2, 14, 119, 245, 364, 427, 490, 609, 728; PrD and 2, 4, 6 hours PoD on Days 28, 56, 182, 301, 546, 672 ]
  • Part 1: Area under the curve (AUC) of RO7034067 [ Time Frame: PrD (Hour 0) and 2, 4, 6, hour PoD on Days 1, 28, 84, 364, 546, 728; PrD on Day 2; PrD and 4 hours PoD on Days 7, 14, 56, 119, 182, 245, 301, 427, 490, 609, 672 ]
  • Part 2: Area under the curve (AUC) of RO7034067 [ Time Frame: 2, 4, 6, hours PoD on Day 1; PrD (Hour 0) on Days 2, 14, 119, 245, 364, 427, 490, 609, 728; PrD and 2, 4, 6 hours PoD on Days 28, 56, 182, 301, 546, 672 ]
  • Part 1: Concentration at the end of a dosing interval (Ctrough) of RO7034067 [ Time Frame: PrD (Hour 0) Days 1, 2, 7, 14, 28, 56, 84, 119, 364, 546 ]
  • Part 2: Concentration at the end of a dosing interval (Ctrough) of RO7034067 [ Time Frame: PrD (Hour 0) on Days 2, 14, 28, 56, 119, 182, 301, 546, 672 ]
  • Time to Death [ Time Frame: Baseline up to 25 Months ]
  • Time to Permanent Ventilation [ Time Frame: Baseline up to 25 Months ]
  • Survival of Motor Neuron (SMN) Protein Levels in Blood [ Time Frame: pre-dose on Day 1, 14, 28, 119, 245, 364, 609, 728 ]
  • Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA) Levels in Blood [ Time Frame: Day 1, 14, 28, 245, 364, 609, 728 ]
  • Change From Baseline in the Total Raw Score of the BSID-III Gross Motor Scale at Month 12 and 24 [ Time Frame: Baseline, Month 12, Month 24 ]
  • Percentage of Infants who Achieve the Attainment Levels of the Motor Milestones Assessed in the Hammersmith Infant Neurological Examination Module 2 (HINE-2) at Month 12 and 24 [ Time Frame: Month 12, Month 24 ]
  • Percentage of Infants who Achieve Highest Motor Milestone as Assessed in the BSID-III Gross Motor Scale [ Time Frame: Month 12, Month 24 ]
  • Percentage of Infants who Achieve a Score of 40 or Higher in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) at Month 12 [ Time Frame: Month 12 ]
  • Percentage of Infants who Achieve a Reduction of 30 Degrees in Their Phase Angle From Baseline, as Measured by Respiratory Inductance Plethysmography at Month 12 [ Time Frame: Baseline, Month 12 ]
  • Percentage of Infants who Achieve an Increase of at Least 0.3 millivolt From Baseline in Their Compound Muscle Action Potential Negative Peak Amplitude at Month 12 and 24 [ Time Frame: Baseline, Month 12, Month 24 ]
  • Time to Death or Permanent Ventilation, Whichever Occurred First [ Time Frame: Baseline up to 25 Months ]
  • Percentage of Infants who are Alive Without Permanent Ventilation at Month 12 and 24 [ Time Frame: Month 12, Month 24 ]
  • Percentage of Infants who are Sitting Without Support at 24-months [ Time Frame: Month 24 ]
  • Percentage of Infants who are Stands Alone as Assessed in Item 40 of the BSID-III Gross Motor Scale at Month 24 [ Time Frame: Month 24 ]
  • Percentage of Infants who are Walks Alone as Assessed in Item 42 of the BSID-III Gross Motor Scale at Month 24 [ Time Frame: Month 24 ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
Official Title  ICMJE A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants With Type 1 Spinal Muscular Atrophy
Brief Summary Open-label, multi-center clinical study is to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and efficacy of Risdiplam (RO7034067) in infants with Type 1 spinal muscular atrophy (SMA). The study consists of two parts, an exploratory dose finding part (Part 1) and a confirmatory part (Part 2) which will investigate Risdiplam (RO7034067) for 24-months at the dose selected in Part 1.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Muscular Atrophy, Spinal
Intervention  ICMJE Drug: Risdiplam
Risdiplam will be administered orally.
Other Name: RO7034067, Evrysdi
Study Arms  ICMJE
  • Experimental: Part 1 (Dose Finding): Risdiplam (RO7034067)
    Participants will receive multiple ascending doses of risdiplam (RO7034067), administered orally once daily for a minimum of 4 weeks to select the dose for Part 2. During the first year of treatment, most participants will switch to the Part 2 dose. During the second year of treatment, all Part 1 participants will be receiving the Part 2 dose. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
    Intervention: Drug: Risdiplam
  • Experimental: Part 2 (Confirmatory): Risdiplam (RO7034067)
    Participants will receive risdiplam (RO7034067), administered orally once daily at the dose defined in Part 1 of the study, for a duration of 24 months. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
    Intervention: Drug: Risdiplam
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: January 15, 2020)
62
Original Estimated Enrollment  ICMJE
 (submitted: September 22, 2016)
48
Estimated Study Completion Date  ICMJE November 17, 2023
Actual Primary Completion Date November 14, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Clinical history, signs or symptoms attributable to Type 1 SMA with onset after 28 days but prior to the age of 3 months
  • Gestational age of 37 to 42 weeks
  • Confirmed diagnosis of 5q-autosomal recessive SMA
  • Participants has two survival motor neuron 2 (SMN2) gene copies, as confirmed by central testing
  • Body weight greater than or equal to (>=) third percentile for age, using appropriate country-specific guidelines
  • Receiving adequate nutrition and hydration (with or without gastrostomy) at the time of screening, in the opinion of the Investigator
  • Adequately recovered from any acute illness at the time of screening and considered well-enough to participate in the opinion of the Investigator

Exclusion Criteria:

  • Concomitant or previous participation in any investigational drug or device study within 90 days prior to screening or 5 half-lives, whichever is longer
  • Concomitant or previous administration of SMN2-targeting antisense oligonucleotide, SMN2 splicing modifier or gene therapy study
  • Any history of cell therapy
  • Hospitalization for pulmonary event within the last 2 months, or planned at the time of screening
  • Presence of clinically relevant electrocardiogram (ECG) abnormalities before study drug administration
  • Unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system diseases
  • Participants requiring invasive ventilation or tracheostomy
  • Participants requiring awake non-invasive ventilation or with awake hypoxemia (arterial oxygen saturation less than [<] 95 percent [%]) with or without ventilator support
  • Participants with a history of respiratory failure or severe pneumonia, and have not fully recovered their pulmonary function at the time of screening
  • Multiple or fixed contractures and/or hip subluxation or dislocation at birth
  • Presence of non-SMA related concurrent syndromes or diseases
  • Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to first dose administration
  • Any inhibitor of cytochrome P450 (CYP) 3A4 and/or any Organic Cation Transporter 2 (OCT-2) and multidrug and toxin extrusion (MATE) substrates taken within 2 weeks and/or any inducer of CYP3A4 taken within 4 weeks (or within 5-times the elimination half-life, whichever is longer) prior to dosing or participants (and the mother, if breastfeeding the infant) taking any nutrients known to modulate CYP3A activity and any known flavin containing monooxygenase (FMO) 1 or FMO3 inhibitors or substrates
  • Prior use (at any time in the participants lives) and/or anticipated need for quinolones (chloroquine and hydroxychloroquine), thioridazine, vigabatrin, retigabine, or any other drug known to cause retinal toxicity during the study. Infants exposed to chloroquine, hydroxycholoroquine, thioridazine, vigabatrin, retigabine or drugs with known retinal toxicity given to mothers during pregnancy (and lactation) should not be enrolled.
  • Recent history (less than 6 months) of ophthalmic disease that would interfere with the conduct of the study as assessed by an ophthalmologist
  • Therapeutic use, defined as use for 8 weeks or longer, of the following medications within 90 days prior to enrollment: riluzole, valproic acid, hydroxyurea, sodium phenylbutyrate, butyrate derivatives, creatine, carnitine, growth hormone, anabolic steroids, probenecid, agents anticipated to increase or decrease muscle strength, agents with known or presumed histone deacetylase (HDAC) inhibitory effect, medications known to or suspected of causing retinal toxicity (deferoxamine, topiramate, latanoprost, niacin, rosiglitazone, tamoxifen, canthaxanthine, sildenafil, and interferon) and medications with known phototoxicity liabilities (e.g., oral retinoids including over-the-counter [OTC] formulations, amiodarone, phenothiazines and use of minocycline)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 1 Month to 7 Months   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Brazil,   China,   Croatia,   France,   Italy,   Japan,   Poland,   Russian Federation,   Saudi Arabia,   Serbia,   Spain,   Switzerland,   Turkey,   Ukraine,   United States
Removed Location Countries Australia,   Germany,   Taiwan
 
Administrative Information
NCT Number  ICMJE NCT02913482
Other Study ID Numbers  ICMJE BP39056
2016-000778-40 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Responsible Party Hoffmann-La Roche
Study Sponsor  ICMJE Hoffmann-La Roche
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Trials Hoffmann-La Roche
PRS Account Hoffmann-La Roche
Verification Date September 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP